Condition
Marginal Zone Lymphomas
Total Trials
4
Recruiting
0
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
P 1 (1)
P 2 (1)
P 3 (2)
Trial Status
Completed2
Not Yet Recruiting1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT02362035Phase 1Completed
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
NCT07008053Phase 2Not Yet RecruitingPrimary
BR Combined With OR in Treatment-naïve Marginal Zone Lymphoma
NCT00991211Phase 3Completed
Bendamustine Plus Rituximab Versus CHOP Plus Rituximab
NCT00877214Phase 3Active Not Recruiting
Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas
Showing all 4 trials